These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17472398)

  • 1. Proniosomal powder of captopril: formulation and evaluation.
    Gupta A; Prajapati SK; Singh M; Balamurugan M
    Mol Pharm; 2007; 4(4):596-9. PubMed ID: 17472398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proniosomes as a drug carrier for transdermal delivery of ketorolac.
    Alsarra IA; Bosela AA; Ahmed SM; Mahrous GM
    Eur J Pharm Biopharm; 2005 Apr; 59(3):485-90. PubMed ID: 15760729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proniosomes as drug carriers.
    Sankar V; Ruckmani K; Durga S; Jailani S
    Pak J Pharm Sci; 2010 Jan; 23(1):103-7. PubMed ID: 20067875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodegradable microparticulate system of captopril.
    Dandagi PM; Mastiholimath VS; Patil MB; Gupta MK
    Int J Pharm; 2006 Jan; 307(1):83-8. PubMed ID: 16310990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled release application of multilamellar vesicles: a novel drug delivery approach.
    Agnihotri SA; Soppimath KS; Betageri GV
    Drug Deliv; 2010 Feb; 17(2):92-101. PubMed ID: 20067375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
    Teeranachaideekul V; Müller RH; Junyaprasert VB
    Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular powder as carrier for doxycycline hydrochloride and metronidazole combination therapy.
    Gad HA; Kamel AO; Sammour OA; El Dessouky HF
    Pharm Dev Technol; 2014 Sep; 19(6):755-68. PubMed ID: 23981239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation.
    Thakur R; Anwer MK; Shams MS; Ali A; Khar RK; Shakeel F; Taha EI
    J Drug Target; 2009 Jul; 17(6):442-9. PubMed ID: 19527115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations.
    Yuksel N; Bayindir ZS; Aksakal E; Ozcelikay AT
    Int J Biol Macromol; 2016 Jan; 82():453-63. PubMed ID: 26455402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
    Mokhtar M; Sammour OA; Hammad MA; Megrab NA
    Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid microparticles for the stability enhancement of the polar drug N6-cyclopentyladenosine.
    Dalpiaz A; Mezzena M; Scatturin A; Scalia S
    Int J Pharm; 2008 May; 355(1-2):81-6. PubMed ID: 18178347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology overview and drug delivery application of proniosome.
    Ahmad MZ; Mohammed AA; Mokhtar Ibrahim M
    Pharm Dev Technol; 2017 May; 22(3):302-311. PubMed ID: 26794727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.
    El-Laithy HM; Shoukry O; Mahran LG
    Eur J Pharm Biopharm; 2011 Jan; 77(1):43-55. PubMed ID: 21056658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysaccharide coated niosomes for oral drug delivery: formulation and in vitro stability studies.
    Sihorkar V; Vyas SP
    Pharmazie; 2000 Feb; 55(2):107-13. PubMed ID: 10723768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maltodextrin-based proniosomes.
    Blazek-Welsh AI; Rhodes DG
    AAPS PharmSci; 2001; 3(1):E1. PubMed ID: 11741252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
    Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of polymeric subcoats on the drug release properties of tablets powder-coated with pre-plasticized Eudragit L 100-55.
    Sauer D; Watts AB; Coots LB; Zheng WC; McGinity JW
    Int J Pharm; 2009 Feb; 367(1-2):20-8. PubMed ID: 18848872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of processing temperature on Eudragit RS PO microsphere characteristics in the solvent evaporation process.
    Sahoo SK; Dhal S; Mohapatro P; Behera BC; Barik BB
    Pharmazie; 2007 Aug; 62(8):638-9. PubMed ID: 17867564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proniosomal powders of natural canthaxanthin: Preparation and characterization.
    Ravaghi M; Sinico C; Razavi SH; Mousavi SM; Pini E; Fadda AM
    Food Chem; 2017 Apr; 220():233-241. PubMed ID: 27855894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.